Cargando…
A phase 2b, randomized, double‐blind, multicenter, vehicle‐controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild‐to‐moderate atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, xerosis, and eczematous lesions. In Japan, treatment options, such as topical corticosteroids and tacrolimus, are associated with efficacy and safety concerns. Crisaborole ointment, 2%, is a topical non‐steroida...
Autores principales: | Fujita, Kayo, Yagi, Michio, Moriwaki, Shinichi, Yoshida, Mizuki, Graham, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292399/ https://www.ncbi.nlm.nih.gov/pubmed/34435694 http://dx.doi.org/10.1111/1346-8138.16120 |
Ejemplares similares
-
Crisaborole for atopic dermatitis
Publicado: (2019) -
Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
por: Fowler, Joseph, et al.
Publicado: (2023) -
Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
por: Luger, Thomas A., et al.
Publicado: (2022) -
Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018) -
Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)